{"id":124880,"date":"2026-06-22T09:09:38","date_gmt":"2026-06-22T03:39:38","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=124880"},"modified":"2026-06-22T09:09:39","modified_gmt":"2026-06-22T03:39:39","slug":"avience-biomedicals-ipo-gmp-day-3","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/","title":{"rendered":"Avience Biomedicals IPO GMP Day 3: GMP Rs 85, 40.9% Listing Premium Expected on NSE SME"},"content":{"rendered":"<div><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Avience Biomedicals IPO GMP Rs 85 (+40.9% premium implied). Price band Rs 196-208. Listing on NSE SME. FY25 revenue Rs 45.97 Cr, PAT Rs 7.23 Cr. Min lot 1200 shares.<\/em><\/p>\n<p style=\"margin-top: 24px;\">The Avience Biomedicals IPO grey market premium has reached Rs 85 on Day 3 of GMP tracking for this NSE SME book-built issue, implying an expected listing price of approximately Rs 293 per share, representing a potential gain of approximately 40.9% over the upper price band of Rs 208. Avience Biomedicals Limited, the Noida-based ISO-certified molecular diagnostics and medical devices manufacturer, is raising Rs 30.24 crore through a 100% fresh issue of 14,53,800 equity shares at a price band of Rs 196 to Rs 208 per share. Kunal Singla, Associate Director at Univest, highlights that the Avience Biomedicals IPO GMP has shown a strong upward trend, rising from Rs 40 in pre-subscription tracking to Rs 70 on Day 1 of subscription and Rs 85 on Day 3 of GMP tracking, reflecting increasing grey market confidence ahead of the final subscription days.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Avience_Biomedicals_IPO_Key_Data_Snapshot\" title=\"Avience Biomedicals IPO: Key Data Snapshot\">Avience Biomedicals IPO: Key Data Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Avience_Biomedicals_IPO_GMP_Day_3_Why_the_Rs_85_Premium_Is_Significant\" title=\"Avience Biomedicals IPO GMP Day 3: Why the Rs 85 Premium Is Significant\">Avience Biomedicals IPO GMP Day 3: Why the Rs 85 Premium Is Significant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Avience_Biomedicals_Business_Model_and_Why_the_Diagnostics_Sector_Attracts_IPO_Investors\" title=\"Avience Biomedicals: Business Model and Why the Diagnostics Sector Attracts IPO Investors\">Avience Biomedicals: Business Model and Why the Diagnostics Sector Attracts IPO Investors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#1_Molecular_Diagnostics_and_IVD_Manufacturer\" title=\"1. Molecular Diagnostics and IVD Manufacturer\">1. Molecular Diagnostics and IVD Manufacturer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#2_Mindray_Channel_Partnership\" title=\"2. Mindray Channel Partnership\">2. Mindray Channel Partnership<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Avience_Biomedicals_IPO_Valuation_and_Risks\" title=\"Avience Biomedicals IPO Valuation and Risks\">Avience Biomedicals IPO Valuation and Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_is_the_Avience_Biomedicals_IPO_GMP_today\" title=\"What is the Avience Biomedicals IPO GMP today?\">What is the Avience Biomedicals IPO GMP today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_is_the_Avience_Biomedicals_IPO_price_band_and_lot_size\" title=\"What is the Avience Biomedicals IPO price band and lot size?\">What is the Avience Biomedicals IPO price band and lot size?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_is_Avience_Biomedicals_business\" title=\"What is Avience Biomedicals&#8217; business?\">What is Avience Biomedicals&#8217; business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_are_Avience_Biomedicals_financial_results\" title=\"What are Avience Biomedicals&#8217; financial results?\">What are Avience Biomedicals&#8217; financial results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_are_Avience_Biomedicals_IPO_risks\" title=\"What are Avience Biomedicals&#8217; IPO risks?\">What are Avience Biomedicals&#8217; IPO risks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_will_Avience_Biomedicals_use_IPO_proceeds_for\" title=\"What will Avience Biomedicals use IPO proceeds for?\">What will Avience Biomedicals use IPO proceeds for?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#What_is_the_significance_of_the_anchor_investor_participation\" title=\"What is the significance of the anchor investor participation?\">What is the significance of the anchor investor participation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-gmp-day-3\/#Should_I_apply_for_Avience_Biomedicals_IPO\" title=\"Should I apply for Avience Biomedicals IPO?\">Should I apply for Avience Biomedicals IPO?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Avience_Biomedicals_IPO_Key_Data_Snapshot\"><\/span><strong>Avience Biomedicals IPO: Key Data Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr>\n<th style=\"background: #1F4E79; color: #fff; padding: 8px 12px; text-align: left;\">Avience Biomedicals IPO Details<\/th>\n<th style=\"background: #1F4E79; color: #fff; padding: 8px 12px; text-align: left;\">Information<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Issue Type<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Book-Built Issue | NSE SME Platform<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Price Band<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Rs 196 to Rs 208 per share (face value Rs 10)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Issue Size<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Rs 30.24 crore (14,53,800 equity shares) | 100% Fresh Issue<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Lot Size<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">600 shares | Min retail: 2 lots (1,200 shares) = Rs 2,49,600 | sNII: 3 lots = Rs 3,74,400<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">GMP (Day 3 of tracking)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Rs 85 (+40.9% premium) | Implied listing ~Rs 293<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Anchor Investors<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Rs 8.52 crore raised from anchor investors<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Listing Exchange<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">NSE SME Platform<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Allotment<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Expected post-close of subscription window<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Business<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Molecular diagnostics, IVD rapid test kits, biochemistry analysers; Noida, UP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">FY25 Revenue \/ PAT<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Rs 45.97 crore (+88.6% YoY) \/ Rs 7.23 crore (+237.9% YoY)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Mindray Partnership<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Channel partner for Mindray biochemistry analysers and haematology equipment<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">Use of Proceeds<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #FFFFFF;\">New manufacturing unit at YEIDA (Medical Device Park), working capital, GCP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Lead Manager \/ Registrar<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #DDD; background: #F4F6F8;\">Fintellectual Corporate Advisors Pvt. Ltd. \/ Skyline Financial Services Pvt. Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"cursor: pointer; background: #E8EAFF; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"margin: 0 0 6px; font-size: 16px; font-weight: bold; color: #0a0a23;\">Research Avience Biomedicals IPO With Univest Expert Analysis<\/p>\n<p style=\"margin: 0 0 12px; font-size: 14px; color: #3d3d5c;\">When Univest analysts track high-GMP IPOs, investors get the full picture.<\/p>\n<p><a style=\"background: #3D5AFE; color: #fff; padding: 8px 20px; border-radius: 4px; text-decoration: none; font-weight: 600; font-size: 14px;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\">Top Stock Picks<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Avience_Biomedicals_IPO_GMP_Day_3_Why_the_Rs_85_Premium_Is_Significant\"><\/span><strong>Avience Biomedicals IPO GMP Day 3: Why the Rs 85 Premium Is Significant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Avience Biomedicals IPO GMP of Rs 85 on Day 3 of tracking is notable because it has strengthened progressively: from Rs 40 on the first pre-subscription day, to Rs 70 on subscription Day 1, to Rs 85 on Day 3 of GMP tracking. This rising GMP trajectory contrasts with many SME IPOs where GMP peaks before subscription opens and then moderates. The strengthening GMP suggests increasing grey market demand as subscription data accumulates. The Avience Biomedicals IPO also secured Rs 8.52 crore from anchor investors, which typically signals institutional confidence and can support a positive listing outcome. However, investors should treat GMP cautiously: it is unofficial, unregulated and can shift substantially between the last subscription day and listing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Avience_Biomedicals_Business_Model_and_Why_the_Diagnostics_Sector_Attracts_IPO_Investors\"><\/span><strong>Avience Biomedicals: Business Model and Why the Diagnostics Sector Attracts IPO Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Molecular_Diagnostics_and_IVD_Manufacturer\"><\/span><strong>1. Molecular Diagnostics and IVD Manufacturer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Avience Biomedicals Limited, founded in 2019 and headquartered in Noida, Uttar Pradesh, is an ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions. The company started with rapid test kits (COVID-19, HIV, malaria, dengue, HBsAg, and related infectious disease diagnostics) and expanded to include serology products, biochemistry analysers, haematology analysers and molecular diagnostics. Avience Biomedicals operates its manufacturing facility in Noida and has also been allotted industrial land in the Medical Device Park at the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh, where it plans to set up a new manufacturing facility using IPO proceeds. The company serves pathology labs, microbiology labs, hospitals, research centres and government bodies across India and some overseas markets through B2B and B2G channels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Mindray_Channel_Partnership\"><\/span><strong>2. Mindray Channel Partnership<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A notable strength of Avience Biomedicals is its channel partnership with Mindray, one of the world&#8217;s leading medical device companies. Through this partnership, Avience Biomedicals can offer Mindray biochemistry analysers and haematology equipment alongside its own manufactured diagnostic kits, creating a comprehensive product offering for hospital and laboratory clients. This partnership also provides Avience with access to Mindray&#8217;s service and training infrastructure, enhancing customer stickiness for the Avience Biomedicals IPO company&#8217;s client relationships.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Avience_Biomedicals_IPO_Valuation_and_Risks\"><\/span><strong>Avience Biomedicals IPO Valuation and Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kunal Singla cautions that the Avience Biomedicals IPO appears fully priced based on the most recent financial data, with the sharp revenue and profit growth in FY25 (revenue +88.6%, PAT +237.9%) partly reflecting post-pandemic diagnostic sector recovery. The sustainability of this growth rate into FY26 and FY27 will be a key question for investors who receive allotment and are considering a hold strategy. Customer concentration risk is significant: the top 10 customers contributed 56.82% of FY25 revenues. SME-specific liquidity risk also applies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Avience Biomedicals IPO GMP stands at Rs 85 on Day 3 of tracking, implying an expected listing price of approximately Rs 293 (+40.9% over Rs 208 upper band). The rising GMP trajectory and Rs 8.52 crore anchor investor participation are positive signals. The company is an ISO-certified molecular diagnostics manufacturer with FY25 revenue of Rs 45.97 crore (+88.6%) and PAT of Rs 7.23 crore (+237.9%). Consult a SEBI-registered financial advisor before investing in SME IPOs.<\/p>\n<p style=\"background: #CC0000; color: #ffffff; padding: 10px 16px;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Please read all scheme-related documents carefully before investing. Univest (Uniresearch Global Pvt Ltd) is a SEBI-registered Research Analyst (INH000013776). Past performance is not indicative of future returns.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Avience_Biomedicals_IPO_GMP_today\"><\/span><strong>What is the Avience Biomedicals IPO GMP today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Avience Biomedicals IPO grey market premium (GMP) stands at Rs 85 on Day 3 of GMP tracking. This implies an expected listing price of approximately Rs 293, representing a potential gain of approximately 40.9% above the upper issue price of Rs 208. The GMP has risen progressively from Rs 40 in pre-subscription tracking to Rs 70 on Day 1 and Rs 85 on Day 3, indicating strengthening grey market demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Avience_Biomedicals_IPO_price_band_and_lot_size\"><\/span><strong>What is the Avience Biomedicals IPO price band and lot size?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Avience Biomedicals IPO price band is Rs 196 to Rs 208 per share (face value Rs 10 each). The lot size is 600 shares. Retail investors must apply for a minimum of 2 lots (1,200 shares), requiring an investment of Rs 2,49,600 at the upper price band of Rs 208. sNII investors must apply for a minimum of 3 lots (1,800 shares) at Rs 3,74,400.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Avience_Biomedicals_business\"><\/span><strong>What is Avience Biomedicals&#8217; business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Avience Biomedicals Limited is a Noida-based ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions. Its products include IVD rapid test kits for COVID-19, HIV, malaria, dengue and HBsAg, along with serology products, biochemistry analysers, haematology analysers and Viral Transport Media (VTM). It also serves as a channel partner for Mindray, distributing biochemistry and haematology equipment. Customers include pathology labs, hospitals, research centres and government bodies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_Avience_Biomedicals_financial_results\"><\/span><strong>What are Avience Biomedicals&#8217; financial results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Avience Biomedicals reported FY25 revenue of Rs 45.97 crore, up approximately 88.6% from Rs 24.37 crore in FY24. Profit after tax grew approximately 237.9% to Rs 7.23 crore from Rs 2.14 crore in FY24. The company had 75 permanent and 33 contractual employees as of the most recent available data. Outstanding borrowings were approximately Rs 26.73 crore. The high revenue and profit growth partly reflects the diagnostic sector recovery trend.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_Avience_Biomedicals_IPO_risks\"><\/span><strong>What are Avience Biomedicals&#8217; IPO risks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks include: customer concentration (top 10 customers contributed 56.82% of FY25 revenues); dependence on third-party suppliers for traded medical devices and raw materials; high borrowings of Rs 26.73 crore; operating history as a relatively young company founded in 2019; sustainability of the FY25 growth rate not guaranteed; and SME-specific liquidity risk post-listing. The issue also appears fully priced at current valuations per analyst commentary. Consult a SEBI-registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_will_Avience_Biomedicals_use_IPO_proceeds_for\"><\/span><strong>What will Avience Biomedicals use IPO proceeds for?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Avience Biomedicals will use the Rs 30.24 crore fresh issue proceeds for: capital expenditure towards setting up a new manufacturing unit at YEIDA (Yamuna Expressway Industrial Development Authority) Medical Device Park, Uttar Pradesh; working capital requirements to support business operations; and general corporate purposes. The new manufacturing unit at the Medical Device Park will expand production capacity for diagnostic kits and medical devices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_significance_of_the_anchor_investor_participation\"><\/span><strong>What is the significance of the anchor investor participation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Avience Biomedicals raised Rs 8.52 crore from anchor investors before the public subscription opened. Anchor investors are qualified institutional buyers (QIBs) who subscribe before the IPO opens and are subject to a mandatory lock-in period post-listing. Anchor investor participation is generally viewed as a positive signal, as it indicates institutional confidence in the company&#8217;s fundamentals and valuation. However, anchor participation does not guarantee listing gains or post-listing stock performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_apply_for_Avience_Biomedicals_IPO\"><\/span><strong>Should I apply for Avience Biomedicals IPO?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Whether to apply for Avience Biomedicals IPO depends on your assessment of the molecular diagnostics growth opportunity, the company&#8217;s ability to sustain FY25-level revenue growth, and your comfort with SME IPO risks. The GMP of Rs 85 implies strong grey market enthusiasm, and anchor investor participation adds a positive signal. However, the issue appears fully priced, customer concentration is high and the SME platform has lower liquidity. Consult a SEBI-registered financial advisor before applying.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Avience Biomedicals IPO GMP today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Avience Biomedicals IPO grey market premium (GMP) stands at Rs 85 on Day 3 of GMP tracking. This implies an expected listing price of approximately Rs 293, representing a potential gain of approximately 40.9% above the upper issue price of Rs 208. The GMP has risen progressively from Rs 40 in pre-subscription tracking to Rs 70 on Day 1 and Rs 85 on Day 3, indicating strengthening grey market demand.\"}},{\"@type\":\"Question\",\"name\":\"What is the Avience Biomedicals IPO price band and lot size?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Avience Biomedicals IPO price band is Rs 196 to Rs 208 per share (face value Rs 10 each). The lot size is 600 shares. Retail investors must apply for a minimum of 2 lots (1,200 shares), requiring an investment of Rs 2,49,600 at the upper price band of Rs 208. sNII investors must apply for a minimum of 3 lots (1,800 shares) at Rs 3,74,400.\"}},{\"@type\":\"Question\",\"name\":\"What is Avience Biomedicals' business?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Avience Biomedicals Limited is a Noida-based ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions. Its products include IVD rapid test kits for COVID-19, HIV, malaria, dengue and HBsAg, along with serology products, biochemistry analysers, haematology analysers and Viral Transport Media (VTM). It also serves as a channel partner for Mindray, distributing biochemistry and haematology equipment. Customers include pathology labs, hospitals, research centres and government bodies.\"}},{\"@type\":\"Question\",\"name\":\"What are Avience Biomedicals' financial results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Avience Biomedicals reported FY25 revenue of Rs 45.97 crore, up approximately 88.6% from Rs 24.37 crore in FY24. Profit after tax grew approximately 237.9% to Rs 7.23 crore from Rs 2.14 crore in FY24. The company had 75 permanent and 33 contractual employees as of the most recent available data. Outstanding borrowings were approximately Rs 26.73 crore. The high revenue and profit growth partly reflects the diagnostic sector recovery trend.\"}},{\"@type\":\"Question\",\"name\":\"What are Avience Biomedicals' IPO risks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks include: customer concentration (top 10 customers contributed 56.82% of FY25 revenues); dependence on third-party suppliers for traded medical devices and raw materials; high borrowings of Rs 26.73 crore; operating history as a relatively young company founded in 2019; sustainability of the FY25 growth rate not guaranteed; and SME-specific liquidity risk post-listing. The issue also appears fully priced at current valuations per analyst commentary. Consult a SEBI-registered financial advisor.\"}},{\"@type\":\"Question\",\"name\":\"What will Avience Biomedicals use IPO proceeds for?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Avience Biomedicals will use the Rs 30.24 crore fresh issue proceeds for: capital expenditure towards setting up a new manufacturing unit at YEIDA (Yamuna Expressway Industrial Development Authority) Medical Device Park, Uttar Pradesh; working capital requirements to support business operations; and general corporate purposes. The new manufacturing unit at the Medical Device Park will expand production capacity for diagnostic kits and medical devices.\"}},{\"@type\":\"Question\",\"name\":\"What is the significance of the anchor investor participation?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Avience Biomedicals raised Rs 8.52 crore from anchor investors before the public subscription opened. Anchor investors are qualified institutional buyers (QIBs) who subscribe before the IPO opens and are subject to a mandatory lock-in period post-listing. Anchor investor participation is generally viewed as a positive signal, as it indicates institutional confidence in the company's fundamentals and valuation. However, anchor participation does not guarantee listing gains or post-listing stock performance.\"}},{\"@type\":\"Question\",\"name\":\"Should I apply for Avience Biomedicals IPO?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Whether to apply for Avience Biomedicals IPO depends on your assessment of the molecular diagnostics growth opportunity, the company's ability to sustain FY25-level revenue growth, and your comfort with SME IPO risks. The GMP of Rs 85 implies strong grey market enthusiasm, and anchor investor participation adds a positive signal. However, the issue appears fully priced, customer concentration is high and the SME platform has lower liquidity. Consult a SEBI-registered financial advisor before applying.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Avience Biomedicals IPO GMP Rs 85 on Day 3, implying listing at ~Rs 293 (+40.9% over Rs 208). NSE SME. FY25 revenue Rs 45.97 Cr (+88.6%), PAT Rs 7.23 Cr (+238%). Molecular diagnostics, Noida.<\/p>\n","protected":false},"author":34,"featured_media":124885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1281],"tags":[4024],"class_list":["post-124880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","tag-ipo-gmp-day-3"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782099583:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["1281"],"rank_math_seo_score":["76"],"rank_math_title":["Avience Biomedicals IPO GMP: Rs 85, 40% Premium Expected"],"rank_math_description":["Avience Biomedicals IPO GMP Rs 85 on Day 3. Implied listing ~Rs 293 (+40.9%). Price band Rs 196-208, NSE SME. FY25 revenue Rs 45.97 Cr (+88.6%), PAT Rs 7.23 Cr (+238%). Molecular diagnostics, Noida."],"rank_math_focus_keyword":["Avience Biomedicals IPO"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["124885"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["19659"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Avience-Biomedicals-IPO-GMP-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/124880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=124880"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/124880\/revisions"}],"predecessor-version":[{"id":124886,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/124880\/revisions\/124886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/124885"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=124880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=124880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=124880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}